Ginkgo Bioworks Holdings, Inc. has reported its financial results for the third quarter of 2026, highlighting significant developments in its operations and growth within the biological products sector. The filing, made on November 9, 2026, reveals the company’s ongoing commitment to innovation and expansion.
Ginkgo Bioworks, known for its work in the biological products industry, focuses on the design of custom microbes for various applications. The company operates under the Standard Industrial Classification (SIC) code 2836, which encompasses biological products excluding diagnostic substances. This sector is crucial for advancements in biotechnology and pharmaceuticals.
Background
Founded in 2008, Ginkgo Bioworks Holdings, Inc. is a leading player in the life sciences space, specifically in biological products. The company trades under the ticker symbol DNA on the New York Stock Exchange (NYSE). As an accelerated filer, Ginkgo is subject to the reporting requirements of the Securities and Exchange Commission (SEC), ensuring transparency and accountability in its operations.
The recent filing is part of Ginkgo's ongoing disclosures, which include a previous 10-Q filed on August 6, 2026, and various 8-K reports detailing significant events and updates. The company continues to engage with investors and stakeholders through regular updates on its financial performance and strategic initiatives.
What the Filing Says
In the latest 10-Q filing, Ginkgo Bioworks reported its financial performance for the period ending September 30, 2026. While specific financial metrics were not disclosed in the summary available, the filing typically includes key data such as revenue, expenses, and earnings per share, which are critical for assessing the company’s financial health and operational efficiency.
Impact
The results from Ginkgo Bioworks' third-quarter report may significantly influence not only its operational strategy but also the broader biological products industry. Investors, analysts, and competitors will be keen to analyze how Ginkgo's performance aligns with industry trends and consumer demands. The biological products sector is highly competitive, with several companies vying for market share in innovative applications.
What's Next
The filing does not specify what happens next for Ginkgo Bioworks. However, stakeholders can expect further updates in the coming months as the company continues to navigate its growth trajectory and respond to market dynamics.
Source: SEC Accession Number 0001628280-26-072290
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










